Breast Cancer Tests Betray ‘Precision Medicine’ Branding
The biotech industry cheered President Obama’s proposed $215 million Precision Medicine Initiative, but the varying results and genetic basis of three DNA-based tests to predict breast cancer recurrence show the gap remaining between branding and real …